Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 80
Filter
1.
Clin Microbiol Infect ; 21(10): 938-45, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26093076

ABSTRACT

Several studies have reported an increased incidence of candidaemia and a redistribution of species, with a decrease in the number of Candida albicans isolates. In Norway, a prospective, national surveillance study of candidaemia has been ongoing since 1991. Data from the period 1991-2003 have been published previously. The aim of this study was to follow up the incidence, species distribution and antifungal susceptibility of Candida species isolates from blood cultures in the period 2004-2012, and compare them with the corresponding findings from the period 1991-2003. Blood culture isolates of Candida species from all medical microbiological laboratories in Norway were identified and susceptibility tested at the Norwegian Mycological Reference Laboratory. A total of 1724 isolates were recovered from 1653 patients in the period 2004-2012. Comparison of the two periods showed that the average incidence of candidaemia episodes per 100 000 inhabitants increased from 2.4 (1991-2003) to 3.9 (2004-2012). The increase in incidence in the latter period was significantly higher in patients aged >40 years (p 0.001), and a marked increase was observed in patients aged >60 years (p < 0.001). In conclusion, the average incidence in Norway over a period of 22 years modestly increased from 2.4 to 3.9 per 100,000 inhabitants, this being mainly accounted for by candidaemia in the elderly. The species distribution was stable, and the rate of acquired resistance was low.


Subject(s)
Candida/classification , Candida/isolation & purification , Candidemia/epidemiology , Candidemia/microbiology , Adolescent , Adult , Age Factors , Aged , Aged, 80 and over , Antifungal Agents/pharmacology , Candida/drug effects , Child , Child, Preschool , Drug Resistance, Fungal , Epidemiological Monitoring , Female , Humans , Incidence , Infant , Infant, Newborn , Male , Microbial Sensitivity Tests , Middle Aged , Norway/epidemiology , Prospective Studies , Young Adult
2.
Emerg Infect Dis ; 21(6): 1041-4, 2015 Jun.
Article in English | MEDLINE | ID: mdl-25988348

ABSTRACT

To investigate azole resistance in clinical Aspergillus isolates, we conducted prospective multicenter international surveillance. A total of 3,788 Aspergillus isolates were screened in 22 centers from 19 countries. Azole-resistant A. fumigatus was more frequently found (3.2% prevalence) than previously acknowledged, causing resistant invasive and noninvasive aspergillosis and severely compromising clinical use of azoles.


Subject(s)
Antifungal Agents/pharmacology , Aspergillosis/epidemiology , Aspergillosis/microbiology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Drug Resistance, Fungal , Population Surveillance , Aspergillus fumigatus/genetics , Humans , Microbial Sensitivity Tests , Mutation , Prevalence , Prospective Studies
3.
Antimicrob Agents Chemother ; 57(12): 5836-42, 2013 Dec.
Article in English | MEDLINE | ID: mdl-24018263

ABSTRACT

Although Clinical and Laboratory Standards Institute (CLSI) clinical breakpoints (CBPs) are available for interpreting echinocandin MICs for Candida spp., epidemiologic cutoff values (ECVs) based on collective MIC data from multiple laboratories have not been defined. While collating CLSI caspofungin MICs for 145 to 11,550 Candida isolates from 17 laboratories (Brazil, Canada, Europe, Mexico, Peru, and the United States), we observed an extraordinary amount of modal variability (wide ranges) among laboratories as well as truncated and bimodal MIC distributions. The species-specific modes across different laboratories ranged from 0.016 to 0.5 µg/ml for C. albicans and C. tropicalis, 0.031 to 0.5 µg/ml for C. glabrata, and 0.063 to 1 µg/ml for C. krusei. Variability was also similar among MIC distributions for C. dubliniensis and C. lusitaniae. The exceptions were C. parapsilosis and C. guilliermondii MIC distributions, where most modes were within one 2-fold dilution of each other. These findings were consistent with available data from the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (403 to 2,556 MICs) for C. albicans, C. glabrata, C. krusei, and C. tropicalis. Although many factors (caspofungin powder source, stock solution solvent, powder storage time length and temperature, and MIC determination testing parameters) were examined as a potential cause of such unprecedented variability, a single specific cause was not identified. Therefore, it seems highly likely that the use of the CLSI species-specific caspofungin CBPs could lead to reporting an excessive number of wild-type (WT) isolates (e.g., C. glabrata and C. krusei) as either non-WT or resistant isolates. Until this problem is resolved, routine testing or reporting of CLSI caspofungin MICs for Candida is not recommended; micafungin or anidulafungin data could be used instead.


Subject(s)
Antifungal Agents/therapeutic use , Candida/drug effects , Candidiasis/drug therapy , Echinocandins/therapeutic use , Anidulafungin , Candida/growth & development , Candida/isolation & purification , Candidiasis/microbiology , Caspofungin , Drug Resistance, Fungal , Europe , Humans , Lipopeptides/therapeutic use , Micafungin , Microbial Sensitivity Tests/standards , Microbial Sensitivity Tests/statistics & numerical data , North America , Observer Variation , South America , Species Specificity
4.
Clin Microbiol Infect ; 17(12): 1875-81, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21745258

ABSTRACT

A longitudinal, prospective study was conducted intermittently in Norway, from 1999 to 2008, to investigate the Candida colonization rates and species distributions in the tonsillopharyngeal and faecal flora in: (i) children with cancer; (ii) children with cystic fibrosis (CF); and (iii) healthy children. The effect of antibiotic treatment on Candida colonization was also studied, and we looked for changes in antifungal susceptibility over time within each child and between the different groups of children. In total, 566 tonsillopharyngeal swabs and 545 faecal samples were collected from 45 children with cancer, 37 children with CF, and 71 healthy, age-matched controls. The overall colonization rate with Candida was not significantly higher in the two groups of children undergoing extensive treatment with broad-spectrum antibiotics than in healthy controls. Approximately one-third of the cancer patients had a total lack of Candida colonization or had only one Candida-positive sample, despite multiple samples being taken, treatment with broad-spectrum antibiotics, long hospital stays, and periods with neutropenia. Children with CF had the highest prevalence of Candida albicans. Amoxycillin, azithromycin, third-generation cephalosporins and oral vancomycin resulted in a significantly increased Candida colonization rate. Phenoxymethylpenicillin, second-generation cephalosporins, metronidazole, trimethoprim-sulphamethoxazole, ciprofloxacin, penicillinase-resistant penicillins and inhaled tobramycin or colistin showed minimal effects on the Candida colonization rate. We found no evidence of development of antifungal resistance over time.


Subject(s)
Candida/classification , Candidiasis/epidemiology , Cystic Fibrosis/complications , Neoplasms/complications , Adolescent , Anti-Bacterial Agents/therapeutic use , Antifungal Agents/pharmacology , Candida/drug effects , Candida/isolation & purification , Child , Child, Preschool , Feces/microbiology , Humans , Infant , Longitudinal Studies , Microbial Sensitivity Tests , Norway/epidemiology , Palatine Tonsil/microbiology , Pharynx/microbiology , Prevalence , Prospective Studies
5.
Clin Microbiol Infect ; 17(12): 1859-67, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21199154

ABSTRACT

Zygomycosis is an important emerging fungal infection, associated with high morbidity and mortality. The Working Group on Zygomycosis of the European Confederation of Medical Mycology (ECMM) prospectively collected cases of proven and probable zygomycosis in 13 European countries occurring between 2005 and 2007. Cases were recorded by a standardized case report form, entered into an electronic database and analysed descriptively and by logistic regression analysis. During the study period, 230 cases fulfilled pre-set criteria for eligibility. The median age of the patients was 50 years (range, 1 month to 87 years); 60% were men. Underlying conditions included haematological malignancies (44%), trauma (15%), haematopoietic stem cell transplantation (9%) and diabetes mellitus (9%). The most common manifestations of zygomycosis were pulmonary (30%), rhinocerebral (27%), soft tissue (26%) and disseminated disease (15%). Diagnosis was made by both histology and culture in 108 cases (44%). Among 172 cases with cultures, Rhizopus spp. (34%), Mucor spp. (19%) and Lichtheimia (formerly Absidia) spp. (19%) were most commonly identified. Thirty-nine per cent of patients received amphotericin B formulations, 7% posaconazole and 21% received both agents; 15% of patients received no antifungal therapy. Total mortality in the entire cohort was 47%. On multivariate analysis, factors associated with survival were trauma as an underlying condition (p 0.019), treatment with amphotericin B (p 0.006) and surgery (p <0.001); factors associated with death were higher age (p 0.005) and the administration of caspofungin prior to diagnosis (p 0.011). In conclusion, zygomycosis remains a highly lethal disease. Administration of amphotericin B and surgery, where feasible, significantly improve survival.


Subject(s)
Zygomycosis/epidemiology , Adolescent , Adult , Age Distribution , Aged , Aged, 80 and over , Antifungal Agents/administration & dosage , Child , Child, Preschool , Diabetes Complications , Europe/epidemiology , Female , Fungi/classification , Fungi/isolation & purification , Hematologic Neoplasms/complications , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Infant , Male , Middle Aged , Prospective Studies , Risk Factors , Sex Distribution , Survival Analysis , Wounds and Injuries/complications , Young Adult , Zygomycosis/mortality
6.
J Hosp Infect ; 76(1): 56-9, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20542590

ABSTRACT

Published data implicate hospital water as a potential source of opportunistic fungi that may cause life-threatening infections in immunocompromised patients. Point-of-care filters are known to retain bacteria, but little is known about their efficacy in reducing exposure to moulds. We investigated the effect of point-of-use filters (Pall-Aquasafe) on the level of contamination of Aspergillus fumigatus and other filamentous fungi. The point-of-use filters were applied to several outlets (taps and showers) on the paediatric bone marrow transplantation (BMT) unit of the National Hospital in Oslo, Norway. In addition the efficacy was investigated using a test rig. The laboratory experiments showed that the filters were highly effective in reducing the number of colony-forming units for a period of at least 15 days. In the BMT unit the filters eliminated the fungi from the water on day 1 but due to particles present in the water the filters occluded, which prevented further evaluations. Our results show that point-of-use filtration might be an effective preventive measure to eliminate filamentous fungi at individual points of water use, thereby reducing patients' exposure.


Subject(s)
Filtration/methods , Fungi/isolation & purification , Point-of-Care Systems , Water Microbiology , Water Purification/methods , Colony Count, Microbial , Hospitals , Humans , Norway
7.
Eur J Clin Microbiol Infect Dis ; 28(10): 1191-8, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19504136

ABSTRACT

In cases of sudden unexpected death in infants and children (SUDI), microbiological investigation has been an important part of the autopsy protocol at the University of Oslo for the last 15 years. The purpose of this study was to compare the microbiological findings in samples taken at hospital admittance shortly after death and at autopsy. Blood cultures and cerebrospinal fluid (CSF) were collected both at the hospital and at autopsy; organ samples were additionally collected at autopsy. Hospital samples were collected at a median of 4.5 h (95% confidence interval [CI] 3.25-5) and autopsy samples at a median of 24.25 h (95% CI 22-25.5) after death. The proportion of positive cultures was stable over time; the post mortal time had no influence on bacterial growth. As long as the autopsy is performed within 48 h after death, prior microbiological examination is unnecessary. Blood culture, CSF and lung specimens are the best predictors in our study.


Subject(s)
Autopsy , Bacterial Infections/blood , Bacterial Infections/cerebrospinal fluid , Infant Mortality , Sudden Infant Death/etiology , Bacterial Infections/mortality , Cause of Death , Humans , Infant , Infant, Newborn , Kidney/microbiology , Kidney/pathology , Liver/microbiology , Liver/pathology , Logistic Models , Lung/microbiology , Lung/pathology , Spleen/microbiology , Spleen/pathology , Sudden Infant Death/pathology , Time Factors
8.
Scand J Immunol ; 68(1): 75-84, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18466195

ABSTRACT

We developed a live Escherichia coli model of acute sepsis in pigs with emphasize on biomarkers reflecting the early inflammatory response of sepsis. Healthy pigs, 25-35 kg, were challenged intravenously (IV) (n = 12) or intrapulmonary (n = 6) with live E. coli and observed for 3 and 5 h respectively. Control pigs received culture medium (n = 6 + 3). Haemodynamic parameters and a broad panel of inflammatory mediators were measured. The dose of bacteria was carefully titrated to obtain a condition resembling the early phase of human septic shock. The IV group displayed a pro-inflammatory response [significant increase in tumour necrosis factor-alpha, interleukin (IL)-6 and IL-8] and an early anti-inflammatory response (significant increase in IL-10). For the first time, we demonstrate a significant increase in IL-12 and matrix metalloproteinase-9 (MMP) early in pig sepsis. Coagulation was activated (significant increase in thrombin-antithrombin complexes) and there was a significant decrease in the serum proteins suggesting capillary leakage. Haemodynamic parameters reflected a septic condition with significant decrease in systemic blood pressure, increases in heart rate, pulmonary artery pressure and base deficit. None of these changes was observed in the control group. Interleukin-1beta and vascular endothelial growth factor increased in both groups. Nitric oxide measurements suggested an initial pulmonary vascular endothelial inflammatory response. The intrapulmonary group, which did not resemble septic condition, showed a substantial increase in MMP-9. In this porcine model of sepsis, IL-12 and MMP-9 were detected for the first time. These biomarkers may have an impact in the understanding and future treatment of sepsis.


Subject(s)
Biomarkers/blood , Inflammation Mediators/blood , Sepsis/blood , Sepsis/physiopathology , Animals , Disease Models, Animal , Escherichia coli , Hemodynamics , Interleukin-12/blood , Matrix Metalloproteinase 9/blood , Sepsis/immunology , Swine
9.
Rheumatology (Oxford) ; 47(7): 1006-11, 2008 Jul.
Article in English | MEDLINE | ID: mdl-18420659

ABSTRACT

OBJECTIVES: To assess the frequency of Streptococcus pyogenes in children with early arthritis, compare the characteristics in patients with post-streptococcal ReA (PSReA) with those in patients with other types of arthritis, and describe the occurrence of carditis in PSRA. PATIENTS: In a population-based Norwegian study, the physicians were asked to refer all children with suspected arthritis. The arthritis patients were followed up at 6 weeks, 6 months and 18 months. The presence of S. pyogenes was based on throat smear or antibodies. Echocardiography was performed in the patients with ARF or PSRA. RESULTS: Thirty-two (18%) of the 173 children with arthritis tested positive for S. pyogenes. The percentage of positive tests rose steadily with age and peaked at ages 8-11 (35%). Six weeks after admission arthritis was present in 33% of the PSRA patients, which was less frequent than in the juvenile idiopathic arthritis (JIA) patients (P < 0.001), but more frequent than in the transient arthritis patients (P = 0.012). Hip arthritis was more frequent and knee/ankle arthritis, ANA and HLA-B27 were less frequent in PSRA than in JIA (P < 0.001, P = 0.009 and P = 0.029, respectively). The PSRA patients were older than those with transient arthritis (P = 0.007). One child with ARF had carditis. CONCLUSIONS: Streptococcus pyogenes was present in 18% of children with arthritis. The patient characteristics, clinical presentation and early disease course in PSRA was different from that of JIA and transient arthritis.


Subject(s)
Arthritis, Reactive/epidemiology , Streptococcal Infections/epidemiology , Streptococcus pyogenes/isolation & purification , Adolescent , Age Distribution , Age Factors , Arthritis/diagnosis , Arthritis/epidemiology , Arthritis, Juvenile/diagnosis , Arthritis, Juvenile/epidemiology , Arthritis, Reactive/diagnosis , Child , Child, Preschool , Diagnosis, Differential , Female , Follow-Up Studies , Humans , Infant , Male , Myocarditis/microbiology , Norway/epidemiology , Pharynx/microbiology , Prohibitins , Streptococcal Infections/diagnosis
10.
J Appl Microbiol ; 102(3): 774-80, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17309627

ABSTRACT

AIMS: In order to determine the occurrence of filamentous fungi in public drinking water systems in Norway, water from 14 water supply networks from all over the country was sampled and analysed. Networks with both ground and surface water sources were included in this study. METHODS AND RESULTS: During a one-year period, 273 water samples were collected. Frequencies of fungi in samples from raw water, treated water and from home and hospital installations were determined on the basis of incubation of 100 ml membrane-filtered samples on dichloran 18% glycerol agar media. Filamentous fungi were recovered from 62% of all samples. In ground water 42.3% of the samples were positive for mould growth, while surface waters yielded 69.7% positive samples. CONCLUSIONS: The risk to recover moulds from surface water is three times higher compared with ground water. It is more likely to detect moulds in cold waters and showers than in hot waters. SIGNIFICANCE AND IMPACT OF THE STUDY: By analysing the water reaching the consumers, the results reported in present study indicate that filamentous fungi in drinking water is not negligible, and that moulds should be considered as part of the microbiological analysis parameters in drinking water.


Subject(s)
Fungi/isolation & purification , Water Microbiology , Water Supply , Culture Media , Drinking , Environmental Monitoring/methods , Fresh Water/microbiology , Hot Temperature , Norway , Risk Assessment/methods , Seasons
11.
Clin Exp Immunol ; 143(1): 65-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16367935

ABSTRACT

The soluble branched yeast beta-1,3-D-glucan (SBG) belongs to a group of carbohydrate polymers known to exert potent immunomodulatory effects when administered to animals and humans. A new oral solution of SBG has been developed for local application to the oropharyngeal and oesophageal mucosa in order to strengthen the defence mechanisms against microbial and toxic influences. In the present study oral administration of SBG has been investigated primarily for assessment of safety and tolerability in an early phase human pharmacological study (phase I). Eighteen healthy volunteers were included among non-smoking individuals. The study was an open 1:1:1 dose-escalation safety study consisting of a screening visit, an administration period of 4 days and a follow-up period. Groups of six individuals received SBG 100 mg/day, 200 mg/day or 400 mg/day, respectively, for 4 consecutive days. The dose increase was allowed after a careful review of the safety data of the lower dose group. No drug-related adverse event, including abnormalities in vital signs, was observed. By inspection of the oral cavity only minor mucosal lesions not related to the study medication were seen in seven subjects. Repeated measurements of beta-glucan in serum revealed no systemic absorption of the agent following the oral doses of SBG. In saliva, the immunoglobulin A concentration increased significantly for the highest SBG dose employed. SBG was thus safe and well tolerated by healthy volunteers, when given orally once daily for 4 consecutive days at doses up to 400 mg.


Subject(s)
Immunoglobulin A/analysis , Immunologic Factors/administration & dosage , Saliva/immunology , beta-Glucans/administration & dosage , Administration, Oral , Adult , Female , Humans , Immunoglobulin G/analysis , Interleukin-1/analysis , Interleukin-6/analysis , Male , Statistics, Nonparametric , Stimulation, Chemical , Tumor Necrosis Factor-alpha/analysis
12.
Acta Paediatr ; 92(2): 254-7, 2003.
Article in English | MEDLINE | ID: mdl-12710657

ABSTRACT

AIM: To present a possible association between cerebral venous thrombosis (CVT) and infection with Escherichia coli. METHODS: Four neonates with deep CVT occurring during an E. coli infection are presented. RESULTS: In these patients the thrombotic disease was found by Doppler ultrasonography. The thrombosis involved at least the sagittal sinus and the transverse sinus according to subsequent MRI scans. The E. coli strains did not produce verotoxin or haemolysin. Disseminated intravascular coagulation was not demonstrated. Three patients presented with seizures. At discharge, all of the patients had signs of neurological damage, but two of them have improved significantly since then. None of the patients has had recurrent (venous) thrombosis. CONCLUSION: E. coli infections in neonates may predispose to CVT, a finding that has clinical implications.


Subject(s)
Escherichia coli Infections/complications , Escherichia coli/pathogenicity , Intracranial Thrombosis/etiology , Venous Thrombosis/etiology , Escherichia coli/isolation & purification , Escherichia coli Infections/diagnosis , Escherichia coli Infections/microbiology , Humans , Infant, Newborn , Intracranial Thrombosis/diagnosis , Intracranial Thrombosis/microbiology , Magnetic Resonance Imaging , Male , Ultrasonography, Doppler , Venous Thrombosis/diagnosis , Venous Thrombosis/microbiology
14.
J Hosp Infect ; 47(2): 143-8, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11170779

ABSTRACT

In order to determine whether water or water-related surfaces are a reservoir for opportunistic filamentous fungi, water sampling in the paediatric bone marrow transplantation (BMT) unit of the National Hospital University of Oslo, Norway was performed. During a six-month period 168 water samples and 20 samples from water-related surfaces were taken. The water samples were taken from the taps and showers in the BMT unit and from the main pipe supplying the paediatric department with water. In addition, 20 water samples were taken at the intake reservoir supplying the city of Oslo with drinking water. Filamentous fungi were recovered from 94% of all the water samples taken inside the hospital with a mean colony forming unit (cfu) count of 2.7/500mL of water. Aspergillus fumigatus was recovered from 49% and 5.6% of water samples from the taps and showers, respectively (mean 1.9 and 1.0cfu/500mL). More than one third (38.8%) of water samples from the main pipe revealed A. fumigatus (mean 2.1cfu/500mL). All water samples taken at the intake reservoir were culture positive for filamentous fungi, 85% of the water samples showed A. fumigatus (mean 3.1cfu/500mL). Twenty-five percent of water-related surfaces yielded filamentous fungi, but A. fumigatus was recovered from only two samples. We showed that filamentous fungi are present in the hospital water and to a lesser extent on water-related surfaces. The recovery of filamentous fungi in water samples taken at the intake reservoir suggests that the source of contamination is located outside the hospital.


Subject(s)
Aspergillus fumigatus/growth & development , Aspergillus fumigatus/isolation & purification , Bone Marrow Transplantation , Fungi/growth & development , Fungi/isolation & purification , Hospital Units , Pediatrics , Water Microbiology , Air Microbiology , Bone Marrow Transplantation/immunology , Child , Equipment Contamination/prevention & control , Equipment Contamination/statistics & numerical data , Hospitals, University , Humans , Infection Control/methods , Norway , Opportunistic Infections , Sampling Studies , Sanitary Engineering/instrumentation
15.
Tidsskr Nor Laegeforen ; 121(26): 3090-4, 2001 Oct 30.
Article in Norwegian | MEDLINE | ID: mdl-11757446

ABSTRACT

BACKGROUND: Bacterial resistance to antibiotics is an increasing threat to the successful treatment of hospital and community-acquired infections. MATERIAL AND METHODS: Based on relevant literature, this article focuses on some of the essential resistance problems caused by pathogens such as pneumococci, staphylocci, enterococci and gram-negative rods, and provides a review of the genetic and molecular basis of bacterial resistance, as well as of the global trends in bacterial resistance. RESULTS: Mechanisms of resistance continue to evolve and disseminate among gram-negative as well as gram-positive pathogens. New problems are developing, such as glycopeptide resistance in Staphylococcus aureus. Bacteria have become resistant to antibiotics as a result of chromosomal changes or the exchange of genetic material via plasmids and transposons. The emergence of multiresistant bacteria e.g. S. aureus, enterococci and Mycobacterium tuberculosis, has made many currently available antibiotics ineffective. INTERPRETATION: The introduction of new antibiotics has always been followed by development of resistance.


Subject(s)
Drug Resistance, Bacterial , Drug Resistance, Bacterial/genetics , Drug Resistance, Bacterial/immunology , Enterococcus/drug effects , Enterococcus/immunology , Gram-Negative Aerobic Rods and Cocci/drug effects , Gram-Negative Aerobic Rods and Cocci/immunology , Humans , Methicillin Resistance/genetics , Methicillin Resistance/immunology , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/immunology , Propionibacterium acnes/drug effects , Propionibacterium acnes/immunology , Staphylococcus aureus/drug effects , Staphylococcus aureus/immunology , Streptococcus pneumoniae/drug effects , Streptococcus pneumoniae/immunology
16.
Nephron ; 86(1): 79-83, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10971157

ABSTRACT

We present a 50-year-old female who experienced generalized convulsion 3 months after a successful cadaveric renal transplantation. The first cerebral CT scan indicated cerebral frontal infarction. Repeat CT some days later revealed progressive lesions, and a highly malignant tumor or abscess was suspected. Antifungal and broad-spectrum antibacterial therapy was initiated. Cerebral MRI could not differentiate between these conditions, but a neutrophil granulocyte scan strongly suggested an infectious process. A stereotactic puncture of the frontal lobe was followed by temporary improvement. A severe progressive left-sided hemiparalysis gave indication for a craniotomy with evacuation of the abscess 9 days later. Culture of aspirated pus yielded growth of a gram-positive, rod-shaped bacterium, later identified as Nocardia otitidiscaviarum by sequencing the 16S rRNA. The patient was treated with meropenem plus rifampicin intravenously for 6 weeks followed by oral ciprofloxacin and rifampicin for 2 months. Due to pharmacokinetic interaction with rifampicin, the prednisolone dose was doubled, and the dose of tacrolimus had to be tripled for maintenance of adequate trough concentrations. Five months following cessation of antibiotic treatment, the patient has regained normal strength and function in her left-sided extremities and has a serum creatinine level of about 160 micromol/l (1.8 mg/dl).


Subject(s)
Anti-Bacterial Agents/therapeutic use , Brain Abscess/therapy , Kidney Transplantation/physiology , Nocardia Infections/therapy , Nocardia/genetics , Brain Abscess/diagnostic imaging , Brain Abscess/etiology , Craniotomy , Female , Humans , Immunosuppressive Agents/therapeutic use , Inhalation , Middle Aged , Nocardia Infections/diagnostic imaging , Nocardia Infections/etiology , Prednisolone/therapeutic use , Radionuclide Imaging , Radiopharmaceuticals , Stereotaxic Techniques , Tacrolimus/therapeutic use , Technetium Tc 99m Exametazime , Tomography, X-Ray Computed
17.
Scand J Infect Dis ; 32(4): 442-4, 2000.
Article in English | MEDLINE | ID: mdl-10959664

ABSTRACT

A 7-y-old boy with relapsed acute lymphatic leukaemia developed fungaemia due to Acremonium strictum, a fungus belonging to the group of the hyaline hyphomycetes. Initially, the fungus was misdiagnosed as Candida sp. due to the presence of abundant adventitious forms. At the time of diagnosis the patient was neutropenic and had a central venous catheter (CVC) in situ. The formation of an occlusive thrombotic mass in the v. subclavia dextra complicated the infection. Treatment consisted of amphotericin B, fluconazole, granulocyte colony-stimulating factor (G-CSF) and removal of the CVC. However the patient responded clinically only after the intravascular thrombus had been removed surgically. Amphotericin B, voriconazole and terbinafine showed high activity in vitro against the Acremonium isolate. A literature review revealed 5 other immunocompromised paediatric patients with a systemic or localized infection due to Acremonium spp.


Subject(s)
Acremonium/isolation & purification , Fungemia/etiology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications , Acremonium/drug effects , Child , Fungemia/drug therapy , Humans , Male
18.
Tidsskr Nor Laegeforen ; 120(15): 1721-5, 2000 Jun 10.
Article in Norwegian | MEDLINE | ID: mdl-10904656

ABSTRACT

BACKGROUND: Each year, 20-25 Norwegian children below the age of 18 are diagnosed with tuberculosis in Norway. MATERIAL AND METHODS: As a demonstration of various difficulties in the work-up and diagnosis of tuberculosis, we present eight infected children aged 15 months to 10 years. RESULTS: Children often contract the infection from adults and may develop serious manifestations including miliary tuberculosis and meningitis. The symptoms are often not specific and tuberculosis may be mistaken for other diseases. Delay and inappropriate diagnostics may have deleterious consequences. INTERPRETATION: The main message is to start treatment upon clinical suspicion of tuberculosis. It is mandatory to sample the necessary biological material for microbiological tests before starting treatment.


Subject(s)
Tuberculosis/diagnosis , Adult , Child , Child, Preschool , Emigration and Immigration , Female , Humans , Infant , Male , Norway/ethnology , Peritonitis, Tuberculous/diagnosis , Tuberculosis/drug therapy , Tuberculosis/transmission , Tuberculosis, Central Nervous System/diagnosis , Tuberculosis, Osteoarticular/diagnosis , Tuberculosis, Pulmonary/diagnosis
19.
Aliment Pharmacol Ther ; 14(2): 233-40, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10651665

ABSTRACT

BACKGROUND: Erythromycin is a motilin agonist and its effects on gastrointestinal motility are dependent on both dose and whether it is administered during the postprandial or fasting state. AIM: To study the motility response of the small bowel to a low dose of intravenous erythromycin after meal intake and during fasting. METHODS: Eighteen healthy subjects with mean age of 25 years were studied by small bowel manometry. Erythromycin was administered intravenously (0.75 mg per kg body weight) during 20 min in the postprandial (n=9) and the fasting state (n=9), and the motility response was recorded. RESULTS: Erythromycin significantly reduced the frequency of propagated contractions (P < 0.001) and the amplitude of contractions (P < 0.02) in the small bowel during established postprandial motility. During the fasting state, erythromycin invariably initiated a phase III-like activity, which was similar to the spontaneous nocturnal phase III and migrated significantly more slowly than the diurnal phase III (P < 0.01). CONCLUSIONS: A low dose of erythromycin administered intravenously during the postprandial state significantly inhibits small bowel motility, whereas administration during the fasting state initiates a phase III resembling the nocturnal rather than the diurnal phase III. These effects of erythromycin may indicate interference with vagal pathways. Due to its inhibitory effects, the clinical use of erythromycin in patients with hypomotility should be reconsidered, and the potential usefulness of these effects in patients with exaggerated intestinal motility deserves further attention.


Subject(s)
Erythromycin/administration & dosage , Fasting/physiology , Food-Drug Interactions/physiology , Gastrointestinal Motility/drug effects , Intestine, Small/drug effects , Adult , Erythromycin/pharmacology , Female , Humans , Infusions, Intravenous , Male , Manometry , Time Factors
20.
Mol Microbiol ; 33(4): 817-27, 1999 Aug.
Article in English | MEDLINE | ID: mdl-10447890

ABSTRACT

Natural competence in Streptococcus pneumoniae is regulated by a quorum-sensing mechanism consisting of a competence-stimulating peptide (CSP), its dedicated secretion apparatus (ComAB), its histidine kinase receptor (ComD) and a response regulator (ComE). In this report, we show that ComE is a DNA-binding protein that acts autocatalytically by binding to a region in its own promoter. Two additional ComE binding sites were identified in the pneumococcal genome, one in the promoter region of comAB and the other upstream of an ABC transporter of unknown function. A comparison of the ComE-binding sequences with the sequence motif previously found to be involved in the co-ordinated expression of the late genes revealed that they are unrelated. These findings indicate that ComE activates transcription of the late genes indirectly, i.e. via one or more intermediate factors.


Subject(s)
Bacterial Proteins/genetics , Streptococcus pneumoniae/genetics , ATP-Binding Cassette Transporters/genetics , Bacterial Proteins/chemistry , Base Sequence , Binding Sites , Blotting, Western , DNA Probes , DNA-Binding Proteins/genetics , Gene Expression Regulation, Bacterial , Molecular Sequence Data , Operon , Promoter Regions, Genetic , Sequence Alignment , Streptococcus pneumoniae/metabolism , Transformation, Bacterial
SELECTION OF CITATIONS
SEARCH DETAIL
...